Clinical Trial Update: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating nemtabrutinib and lisocabtagene maraleucel for relapsed/refractory chronic lymphocytic leukemia and small lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lisocabtagene maraleucel (lisocabtagene maraleucel)
• Nemtabrutinib (nemtabrutinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING